Empagliflozin in Patients with Chronic Kidney Disease

BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligib...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Herrington, William G., Staplin, Natalie, Wanner, Christoph, Green, Jennifer B., Hauske, Sibylle J., Emberson, Jonathan R., Preiss, David, Judge, Parminder, Mayne, Kaitlin J., Ng, Sarah Y.A., Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K., Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P., Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R., Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J., Baigent, Colin, Haynes, Richard
Format: Artigo
Jezik:Inglês
Izdano: 2023
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614055/
https://ncbi.nlm.nih.gov/pubmed/36331190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2204233
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items